Agilent Biopharma Summit 2026 Day 2

Biopharma Innovations Summit: From Discovery to Manufacturing Excellence

oin us for this second annual two-day virtual event where Agilent will explore technologies that advance biopharmaceutical development and manufacturing. The first day focuses on discovery and development, featuring cell analysis, automated electrophoresis, Bravo automation, laboratory robotics, and sustainability initiatives. Day two highlights manufacturing and quality control, covering liquid chromatography, ultra-inert columns, online LC process monitoring, Infinity II 2D-LC, UV-Vis automation, and Multi-Attribute Method (MAM) workflows.

Attend this free event to gain practical insights that improve efficiency, product quality, compliance, and decision-making across the biopharma lifecycle.

By attending this event, you will:

• Apply advanced analytical technologies to accelerate biopharmaceutical discovery, development, and characterization
• Understand how automation and robotics improve laboratory efficiency, throughput, and reproducibility
• Enhance process monitoring and quality control using innovative analytical and digital workflows
• Support compliance and sustainability goals across biopharmaceutical development and manufacturing

8 October - Manufacturing & QC

Intro

Overview of the Day

• Presented by Vitan Blagotinsek, Agilent Technologies

Highlight talk

End-to-End Inert Workflow Solutions for Biopharma Analysis

• Presented by Katrien Sabbe, Agilent Technologies

Nonspecific interactions of analytes with metal surfaces along the LC flowpath can lead to signal suppression, poor peak-shape and reduced recovery. Agilent’s powerful combination of bio-inert and bio-compatible Infinity III LC instruments with Altura Ultra Inert columns and inert LC supplies ensures optimum system performance for metal-sensitive biologically relevant molecules such as peptides, oligonucleotides, Mabs or AAV’s. This results in more confident results, superior data quality, cost
savings and operational efficiency when analyzing next-generation biotherapeutics.

Talk 1

Implementation of Online HPLC for Integrated and Intensified Downstream Processes

• Presented by Julia Müller, FHNW and Jens Trafkowski, Agilent Technologies

Downstream processing remains a major bottleneck in the production of complex biologics such as plasmid DNA and recombinant adeno associated viruses. This work presents an automated online HPLC framework integrated directly into continuous downstream workflows using the Agilent 1290 Infinity III Bio Online LC system. Direct coupling to the process stream enables rapid analytical feedback with minimal manual handling. In particular, real-time breakthrough monitoring during column loading allows precise determination of breakthrough capacity and optimized load termination, supporting
faster process development and scalable automated process control.

Talk 2

Evaluation of a 2D-LC Methodology for Encapsulation Efficiency Determination of Oligonucleotide-Loaded LNPs

• Presented by Sören Planckaert, Eurofins CDMO

Two-dimensional liquid chromatography (2D-LC) is an emerging tool for the characterization of lipid nanoparticles (LNPs) and their nucleic acid payloads. Unlike dye-based fluorescence assays, LC-based encapsulation efficiency (EE) methods provide improved robustness and specificity while reducing matrix- and detergent-related interferences. We developed an in-house 2D-LC method on an Agilent 1290 Infinity II platform for EE determination of nucleic acid-loaded LNPs. Different first-dimension (1D) separation strategies, including hydrophobic interaction chromatography (HIC) and weak anion-exchange (IEX) chromatography, were evaluated prior to second-dimension ion-pair reversed-phase (IP-RP) analysis. This work provides a flexible, open, and broadly accessible framework for LNP EE determination.

Talk 3

UV-Vis Automation – A Path to Pharma Compliance

• Presented by Garry Wright, Paolo Scardina, Wesam Alwan, and Upendra R Anumala, Agilent Technologies

This webinar explores how the Agilent Cary 3500 UV-Vis system delivers compliance, confidence, and automation for modern laboratories on top of biopharma advantages that make the Cary 3500 a compelling choice. It
examines the update of all major pharmacopeia requirements and Agilent’s new UV-Vis protocol with USP, EP, and JP options for streamlined qualification. Attendees will learn how validation starter kits and expert CSV consulting
accelerate regulatory readiness, and how the Cary 3500 SDK enables custom automation beyond the standard workstation.

Talk 4

How to Implement HRMS for Fast and Reliable mAbs Analysis: A New MAM Workflow

• Presented by Charlotte Lekieffre, Agilent Technologies

Multi-Attribute Method (MAM) has the potential to transform biopharmaceutical quality control by consolidating multiple assays into a single LC-HRMS workflow. However, widespread adoption in regulated QC laboratories requires solutions that are robust, simple, and operationally practical. In this presentation, we will showcase Agilent's integrated MAM workflow, combining hardware, software, columns, standards, and consumables to support routine implementation. We will discuss how the workflow streamlines data acquisition, analysis, and reporting while facilitating method transfer from development to QC, enabling laboratories to confidently bring MAM into everyday use.